Published in Neurology on December 10, 2008
The radiologically isolated syndrome: take action when the unexpected is uncovered? J Neurol (2010) 1.09
Use of Magnetic Resonance Imaging as Well as Clinical Disease Activity in the Clinical Classification of Multiple Sclerosis and Assessment of Its Course: A Report from an International CMSC Consensus Conference, March 5-7, 2010. Int J MS Care (2012) 0.79
Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial. Ann Neurol (2009) 3.35
Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta. Lancet Neurol (2010) 3.05
IM interferon beta-1a delays definite multiple sclerosis 5 years after a first demyelinating event. Neurology (2006) 2.43
Decreased FOXP3 levels in multiple sclerosis patients. J Neurosci Res (2005) 2.39
"Undiagnosing" multiple sclerosis: the challenge of misdiagnosis in MS. Neurology (2012) 1.94
Cyclophilin D inactivation protects axons in experimental autoimmune encephalomyelitis, an animal model of multiple sclerosis. Proc Natl Acad Sci U S A (2007) 1.76
Summary of evidence-based guideline: complementary and alternative medicine in multiple sclerosis: report of the guideline development subcommittee of the American Academy of Neurology. Neurology (2014) 1.54
Imbalance in multiple sclerosis: a result of slowed spinal somatosensory conduction. Somatosens Mot Res (2008) 1.42
Axonal degeneration in multiple sclerosis: the mitochondrial hypothesis. Curr Neurol Neurosci Rep (2009) 1.37
Defining interferon beta response status in multiple sclerosis patients. Ann Neurol (2004) 1.34
Centella asiatica accelerates nerve regeneration upon oral administration and contains multiple active fractions increasing neurite elongation in-vitro. J Pharm Pharmacol (2005) 1.33
Interferon-beta-1a treatment increases CD56bright natural killer cells and CD4+CD25+ Foxp3 expression in subjects with multiple sclerosis. J Neuroimmunol (2009) 1.17
Inflammatory neurological disease in patients treated with tumor necrosis factor alpha inhibitors. Mult Scler (2011) 1.16
Partial MHC class II constructs inhibit MIF/CD74 binding and downstream effects. Eur J Immunol (2013) 1.04
Falls requiring medical attention among veterans with multiple sclerosis: a cohort study. J Rehabil Res Dev (2011) 1.02
Activation of the mitochondrial permeability transition pore modulates Ca2+ responses to physiological stimuli in adult neurons. Eur J Neurosci (2011) 1.02
Cognitive dysfunction in multiple sclerosis: natural history, pathophysiology and management. CNS Drugs (2002) 1.01
The radiologically isolated syndrome: look (again) before you treat. Curr Neurol Neurosci Rep (2011) 1.01
Significance of T2 lesions in multiple sclerosis: A 13-year longitudinal study. Ann Neurol (2006) 1.00
Immunotherapy and multiple sclerosis: The devil is in the details. Neurology (2010) 0.98
Prevalence of brain magnetic resonance imaging meeting Barkhof and McDonald criteria for dissemination in space among headache patients. Mult Scler (2013) 0.95
Oxidative stress inhibits axonal transport: implications for neurodegenerative diseases. Mol Neurodegener (2012) 0.94
Disability progression in a clinical trial of relapsing-remitting multiple sclerosis: eight-year follow-up. Arch Neurol (2010) 0.94
Recombinant T-Cell Receptor Ligand (RTL) for Treatment of Multiple Sclerosis: A Double-Blind, Placebo-Controlled, Phase 1, Dose-Escalation Study. Autoimmune Dis (2012) 0.93
A randomized placebo-controlled pilot trial of omega-3 fatty acids and alpha lipoic acid in Alzheimer's disease. J Alzheimers Dis (2014) 0.91
Genetic inactivation of the p66 isoform of ShcA is neuroprotective in a murine model of multiple sclerosis. Eur J Neurosci (2012) 0.91
Epitope spreading is not required for relapses in experimental autoimmune encephalomyelitis. J Immunol (2003) 0.90
Lipoic acid decreases inflammation and confers neuroprotection in experimental autoimmune optic neuritis. J Neuroimmunol (2011) 0.90
Fingolimod and multiple sclerosis: four cautionary tales. Neurology (2012) 0.90
Complementary and alternative medicine for the treatment of multiple sclerosis. Expert Rev Clin Immunol (2010) 0.89
Predicting falls in people with multiple sclerosis: fall history is as accurate as more complex measures. Mult Scler Int (2013) 0.88
Complementary and alternative medicine in multiple sclerosis: survey of licensed naturopaths. J Altern Complement Med (2004) 0.87
Tumefactive multiple sclerosis and fingolimod: Immunotherapies and unintended consequences. Neurology (2013) 0.87
Novel method for measurement of fatigue in multiple sclerosis: Real-Time Digital Fatigue Score. J Rehabil Res Dev (2010) 0.87
Mitochondrial calcium and its regulation in neurodegeneration induced by oxidative stress. Eur J Neurosci (2011) 0.87
Ginkgo biloba does not improve cognitive function in MS: a randomized placebo-controlled trial. Neurology (2012) 0.84
People with multiple sclerosis use many fall prevention strategies but still fall frequently. Arch Phys Med Rehabil (2013) 0.83
Neuroregenerative and neuroprotective actions of neuroimmunophilin compounds in traumatic and inflammatory neuropathies. Neurol Res (2004) 0.83
Complementary and alternative medicine: is there a role in multiple sclerosis? Curr Neurol Neurosci Rep (2006) 0.83
Mitochondrial dysfunction and neurodegeneration in multiple sclerosis. Front Physiol (2013) 0.83
Perceived stress in multiple sclerosis: the potential role of mindfulness in health and well-being. J Evid Based Complementary Altern Med (2014) 0.81
Autoantibodies and Sjogren's Syndrome in multiple sclerosis, a reappraisal. PLoS One (2013) 0.81
Recent developments in multiple sclerosis therapeutics. BMC Med (2009) 0.79
New disease-modifying therapies and new challenges for MS. Curr Neurol Neurosci Rep (2012) 0.79
Genetic inactivation of mitochondria-targeted redox enzyme p66ShcA preserves neuronal viability and mitochondrial integrity in response to oxidative challenges. Front Physiol (2012) 0.78
Frequency-modulation (FM) technology as a method for improving speech perception in noise for individuals with multiple sclerosis. J Am Acad Audiol (2006) 0.78
Nonmyelin-specific T cells accelerate development of central nervous system APC and increase susceptibility to experimental autoimmune encephalomyelitis. J Immunol (2003) 0.77
A randomized pilot study of naturopathic medicine in multiple sclerosis. J Altern Complement Med (2008) 0.77
Postmarketing adverse drug reactions: A duty to report? Neurol Clin Pract (2013) 0.77
Remyelination and multiple sclerosis: therapeutic approaches and challenges. Curr Neurol Neurosci Rep (2014) 0.77
Focal increases of axoplasmic Ca2+, aggregation of sodium-calcium exchanger, N-type Ca2+ channel, and actin define the sites of spheroids in axons undergoing oxidative stress. J Neurosci (2012) 0.77
The use of flow cytometry to assess a novel drug efficacy in multiple sclerosis. Metab Brain Dis (2014) 0.75
Ischemia and multiple sclerosis: perfusion MR imaging provides insight into an underexplored pathophysiology. AJNR Am J Neuroradiol (2005) 0.75
Oral disease-modifying therapies for multiple sclerosis: are we there yet? Curr Neurol Neurosci Rep (2010) 0.75
New oral disease-modifying therapies for multiple sclerosis. F1000 Med Rep (2009) 0.75
The radiologically isolated syndrome revisited: when is it presymptomatic multiple sclerosis? Neurology (2011) 0.75
Reply: To PMID 19798640. Ann Neurol (2010) 0.75
Depression is a treatable cause of suffering among multiple sclerosis patients and can result in suicide. Neurology (2002) 0.75
B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. Curr Neurol Neurosci Rep (2008) 0.75
Increased hippocampal volume in schizophrenics' parents with ancestral history of schizophrenia. Schizophr Res (2002) 0.75
Interruption of natalizumab therapy for multiple sclerosis: what are the risks? Neurology (2011) 0.75
Non-small-cell lung cancer with brain metastasis. Oncology (Williston Park) (2004) 0.75
Anti-NMDA receptor encephalitis with paroxysmal sympathetic hyperactivity: an under-recognized association? Clin Auton Res (2012) 0.75
MS and bone marrow transplant: Not for most patients. Neurology (2017) 0.75
Early Fever As a Predictor of Paroxysmal Sympathetic Hyperactivity in Traumatic Brain Injury. J Head Trauma Rehabil (2017) 0.75
Does interferon beta-1a impact pure-tone hearing sensitivity among individuals with multiple sclerosis? J Neurosci Nurs (2014) 0.75